StreetInsider.com News Articles

Form 4 LivaNova PLC For: Aug 11 Filed by: Tezel Ahmet

Thu, 13 Aug 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260813/26920637.html

Form 4 LivaNova PLC For: Aug 11 Filed by: Tezel Ahmet

Thu, 13 Aug 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260813/26920637.html

Form 144 LivaNova PLC Filed by: Tezel Ahmet

Tue, 11 Aug 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260811/26905840.html

Form 144 LivaNova PLC Filed by: Tezel Ahmet

Tue, 11 Aug 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260811/26905840.html

Form SCHEDULE 13G LivaNova PLC Filed by: FMR LLC

Thu, 06 Aug 2026 10:31:00 -0400

si-local-file:///var/storage/secattach/20260806/26881223.html

Form SCHEDULE 13G LivaNova PLC Filed by: FMR LLC

Thu, 06 Aug 2026 10:31:00 -0400

si-local-file:///var/storage/secattach/20260806/26881223.html

Form IRANNOTICE LivaNova PLC

Wed, 05 Aug 2026 14:27:00 -0400

si-local-file:///var/storage/secattach/20260805/26873039.html

Form IRANNOTICE LivaNova PLC

Wed, 05 Aug 2026 14:27:00 -0400

si-local-file:///var/storage/secattach/20260805/26873039.html

Form 10-Q LivaNova PLC For: Jun 30

Wed, 05 Aug 2026 14:24:00 -0400

si-local-file:///var/storage/secattach/20260805/26873028.html

Form 10-Q LivaNova PLC For: Jun 30

Wed, 05 Aug 2026 14:24:00 -0400

si-local-file:///var/storage/secattach/20260805/26873028.html

Livanova (LIVN) PT Raised to $85 at Stifel

Wed, 05 Aug 2026 13:44:52 -0400

Stifel analyst Rick Wise raised the price target on Livanova (NASDAQ: LIVN) to $85.00 (from $80.00) while maintaining a Buy rating.

Livanova (LIVN) PT Raised to $93 at Needham

Wed, 05 Aug 2026 13:07:44 -0400

(Updated - August 5, 2026 1:07 PM EDT)

Needham analyst Mike Matson raised the price target on Livanova (NASDAQ: LIVN) to $93.00 (from $81.00) while maintaining a Buy rating.

The analyst commented: "LIVN's 2Q26 revenue and EPS beat consensus and LIVN raised its 2026 organic revenue and EPS guidance. Organic revenue growth slowed to 9.8% in 2Q26 from 11.1% in 1Q26. Both LIVN's Cardiopulmonary and Neuromodulation businesses beat consensus. Neuromodulation saw stronger growth while Cardiopulmonary saw slower growth. Gross margin was up 210 bps Y/Y due to tariff refunds (which added ~150 bps), mix, and currency and operating margin was up 130

Livanova (LIVN) PT Raised to $93 at Needham

Wed, 05 Aug 2026 13:07:44 -0400

(Updated - August 5, 2026 1:07 PM EDT)

Needham analyst Mike Matson raised the price target on Livanova (NASDAQ: LIVN) to $93.00 (from $81.00) while maintaining a Buy rating.

Form 3 LivaNova PLC For: Aug 01 Filed by: Folli Stefano

Wed, 05 Aug 2026 06:06:00 -0400

si-local-file:///var/storage/secattach/20260805/26869508.html

Form 3 LivaNova PLC For: Aug 01 Filed by: Folli Stefano

Wed, 05 Aug 2026 06:06:00 -0400

si-local-file:///var/storage/secattach/20260805/26869508.html

Form 8-K LivaNova PLC For: Aug 05

Wed, 05 Aug 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260805/26869507.html

Form 8-K LivaNova PLC For: Aug 05

Wed, 05 Aug 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260805/26869507.html

LivaNova plc (LIVN) Tops Q2 EPS by 17c ; Offers Guidance

Wed, 05 Aug 2026 06:04:07 -0400

LivaNova plc (NASDAQ: LIVN) reported Q2 EPS of $1.26, $0.17 better than the analyst estimate of $1.09. Revenue for the quarter came in at $390.6 million versus the consensus estimate of $380.57 million.

GUIDANCE:

LivaNova plc sees FY2026 EPS of $4.30-$4.40, versus the consensus of $4.25.

For earnings history and earnings-related data on LivaNova plc (LIVN) click here.

LivaNova plc (LIVN) Tops Q2 EPS by 17c ; Offers Guidance

Wed, 05 Aug 2026 06:04:07 -0400

GUIDANCE:

LivaNova plc sees FY2026 EPS of $4.30-$4.40, versus the consensus of $4.25.

For earnings history and earnings-related data on LivaNova plc (LIVN) click here.

LivaNova Reports Second-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance

Wed, 05 Aug 2026 06:00:00 -0400

– Delivered double-digit reported revenue growth of 10.8%, with constant-currency revenue growth of 9.8%

– Raised full-year 2026 revenue and adjusted diluted earnings per share guidance(1)

– Entered into a long-term agreement with Thermo Fisher Scientific to strengthen oxygenator component supply to expand manufacturing output and satisfy unmet demand

GLOUCESTER, England--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the second quarter ended June 30, 2026 and raised full-year 2026 guidance.

Financial Summary and Highlights(1)

Second-quarter revenue of $390.6 million increased 10.8% on a reported basis and 9.8% on a constant-currency basis as compared

LivaNova Reports Second-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance

Wed, 05 Aug 2026 06:00:00 -0400

– Delivered double-digit reported revenue growth of 10.8%, with constant-currency revenue growth of 9.8%

– Raised full-year 2026 revenue and adjusted diluted earnings per share guidance(1)

– Entered into a long-term agreement with Thermo Fisher Scientific to strengthen oxygenator component supply to expand manufacturing output and satisfy unmet demand

Financial Summary and Highlights(1)

Second-quarter revenue of $390.6 million increased 10.8% on a reported basis and 9.8% on a constant-currency basis as compared

LivaNova Reports Second-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance

Wed, 05 Aug 2026 06:00:00 -0400

– Delivered double-digit reported revenue growth of 10.8%, with constant-currency revenue growth of 9.8%

– Raised full-year 2026 revenue and adjusted diluted earnings per share guidance(1)

– Entered into a long-term agreement with Thermo Fisher Scientific to strengthen oxygenator component supply to expand manufacturing output and satisfy unmet demand

Financial Summary and Highlights(1)

Second-quarter revenue of $390.6 million increased 10.8% on a reported basis and 9.8% on a constant-currency basis as compared

LivaNova Reports Second-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance

Wed, 05 Aug 2026 06:00:00 -0400

– Delivered double-digit reported revenue growth of 10.8%, with constant-currency revenue growth of 9.8%

– Raised full-year 2026 revenue and adjusted diluted earnings per share guidance(1)

– Entered into a long-term agreement with Thermo Fisher Scientific to strengthen oxygenator component supply to expand manufacturing output and satisfy unmet demand

Financial Summary and Highlights(1)

Second-quarter revenue of $390.6 million increased 10.8% on a reported basis and 9.8% on a constant-currency basis as compared

LivaNova Reports Second-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance

Wed, 05 Aug 2026 06:00:00 -0400

– Delivered double-digit reported revenue growth of 10.8%, with constant-currency revenue growth of 9.8%

– Raised full-year 2026 revenue and adjusted diluted earnings per share guidance(1)

– Entered into a long-term agreement with Thermo Fisher Scientific to strengthen oxygenator component supply to expand manufacturing output and satisfy unmet demand

Financial Summary and Highlights(1)

Second-quarter revenue of $390.6 million increased 10.8% on a reported basis and 9.8% on a constant-currency basis as compared

LivaNova Reports Second-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance

Wed, 05 Aug 2026 06:00:00 -0400

– Delivered double-digit reported revenue growth of 10.8%, with constant-currency revenue growth of 9.8%

– Raised full-year 2026 revenue and adjusted diluted earnings per share guidance(1)

– Entered into a long-term agreement with Thermo Fisher Scientific to strengthen oxygenator component supply to expand manufacturing output and satisfy unmet demand

Financial Summary and Highlights(1)

Second-quarter revenue of $390.6 million increased 10.8% on a reported basis and 9.8% on a constant-currency basis as compared